Real-world cost–effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China. (May 2017)

• Record Type: Journal Article
• Authors: Li, Jingyang; Wen, Zhenhua; Cai, Anlie; Tian, Feng; Zhang, Liang; Luo, Xiaowen; Deng, Li; He, Jingyun; Yang, Yicheng; Chen, Wendong
• Is Part Of: Journal of comparative effectiveness research. Volume 6:Number 3(2017)
• Page Start: 205
• Page End: 218
• Publication Date: 2017-05
• Subjects: China -- cost–effectiveness -- infliximab -- rheumatoid arthritis; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer-2016-0086
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: To assess the cost–effectiveness of infliximab-containing therapy (ICT) for moderate-to-severe rheumatoid arthritis (RA) in a medium-sized Chinese city.Methods: A Chinese prospective cohort study comparing ICT (25 patients) versus conventional disease-modified antirheumatic drugs (24 patients) for RA was used to assess the cost–effectiveness of ICT.Results: The cohort study observed significantly reduced disease activity score of 28 joints (coefficient -2.718, p < 0.001), improved EQ-5D (coefficient 0.453, p < 0.001) and increased medical costs (coefficient 1.289, p < 0.001) associated with ICT. The incremental cost–effectiveness ratio per gained quality-adjusted life year for ICT versus disease-modified antirheumatic drugs was 1.897-times of the local gross domestic product per capita.Conclusion: Infliximab was a favorable cost-effective alternative option for moderate-to-severe RA in a medium-sized city of China.